nodes	percent_of_prediction	percent_of_DWPC	metapath
Methyl aminolevulinate—FCGR1A—FCGR activation—FCGR3A—atherosclerosis	0.0873	0.211	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Role of phospholipids in phagocytosis—FCGR3A—atherosclerosis	0.0518	0.125	CbGpPWpGaD
Methyl aminolevulinate—Macular oedema—Niacin—atherosclerosis	0.0474	0.0809	CcSEcCtD
Methyl aminolevulinate—Skin burning sensation—Niacin—atherosclerosis	0.0474	0.0809	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Regulation of actin dynamics for phagocytic cup formation—FCGR3A—atherosclerosis	0.0268	0.0647	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Fcgamma receptor (FCGR) dependent phagocytosis—FCGR3A—atherosclerosis	0.0202	0.0488	CbGpPWpGaD
Methyl aminolevulinate—Skin hyperpigmentation—Niacin—atherosclerosis	0.0195	0.0332	CcSEcCtD
Methyl aminolevulinate—Burning sensation—Niacin—atherosclerosis	0.0167	0.0284	CcSEcCtD
Methyl aminolevulinate—Eye irritation—Lovastatin—atherosclerosis	0.0158	0.0269	CcSEcCtD
Methyl aminolevulinate—Skin ulcer—Niacin—atherosclerosis	0.0149	0.0254	CcSEcCtD
Methyl aminolevulinate—Rash pustular—Niacin—atherosclerosis	0.0145	0.0248	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Antigen processing-Cross presentation—NCF1—atherosclerosis	0.0143	0.0345	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Antigen processing-Cross presentation—CYBA—atherosclerosis	0.0134	0.0325	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Interferon gamma signaling—VCAM1—atherosclerosis	0.0123	0.0297	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Interferon gamma signaling—SOCS3—atherosclerosis	0.0119	0.0288	CbGpPWpGaD
Methyl aminolevulinate—Dermatitis contact—Niacin—atherosclerosis	0.0114	0.0195	CcSEcCtD
Methyl aminolevulinate—Skin exfoliation—Niacin—atherosclerosis	0.0111	0.0189	CcSEcCtD
Methyl aminolevulinate—Swelling—Simvastatin—atherosclerosis	0.0104	0.0177	CcSEcCtD
Methyl aminolevulinate—Eczema—Simvastatin—atherosclerosis	0.0102	0.0174	CcSEcCtD
Methyl aminolevulinate—Eczema—Niacin—atherosclerosis	0.00936	0.016	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Antigen processing-Cross presentation—CD36—atherosclerosis	0.00897	0.0217	CbGpPWpGaD
Methyl aminolevulinate—Dermatitis bullous—Niacin—atherosclerosis	0.0088	0.015	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Interferon gamma signaling—ICAM1—atherosclerosis	0.00836	0.0202	CbGpPWpGaD
Methyl aminolevulinate—Face oedema—Niacin—atherosclerosis	0.00812	0.0138	CcSEcCtD
Methyl aminolevulinate—Photosensitivity reaction—Lovastatin—atherosclerosis	0.00772	0.0132	CcSEcCtD
Methyl aminolevulinate—Photosensitivity reaction—Ezetimibe—atherosclerosis	0.00758	0.0129	CcSEcCtD
Methyl aminolevulinate—Photosensitivity reaction—Simvastatin—atherosclerosis	0.00723	0.0123	CcSEcCtD
Methyl aminolevulinate—Photosensitivity reaction—Pravastatin—atherosclerosis	0.00653	0.0111	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Interferon gamma signaling—IFNG—atherosclerosis	0.00636	0.0154	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Interferon Signaling—VCAM1—atherosclerosis	0.006	0.0145	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Interferon Signaling—SOCS3—atherosclerosis	0.00582	0.0141	CbGpPWpGaD
Methyl aminolevulinate—Erythema—Ezetimibe—atherosclerosis	0.00578	0.00987	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Class I MHC mediated antigen processing & presentation—NCF1—atherosclerosis	0.00571	0.0138	CbGpPWpGaD
Methyl aminolevulinate—Infection—Rosuvastatin—atherosclerosis	0.00564	0.00962	CcSEcCtD
Methyl aminolevulinate—Erythema—Simvastatin—atherosclerosis	0.00552	0.00941	CcSEcCtD
Methyl aminolevulinate—Eye disorder—Niacin—atherosclerosis	0.00544	0.00927	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Class I MHC mediated antigen processing & presentation—CYBA—atherosclerosis	0.00537	0.013	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Regulation of actin dynamics for phagocytic cup formation—MAPK3—atherosclerosis	0.0053	0.0128	CbGpPWpGaD
Methyl aminolevulinate—Paraesthesia—Rosuvastatin—atherosclerosis	0.0051	0.0087	CcSEcCtD
Methyl aminolevulinate—Erythema—Niacin—atherosclerosis	0.00506	0.00864	CcSEcCtD
Methyl aminolevulinate—Discomfort—Lovastatin—atherosclerosis	0.00496	0.00846	CcSEcCtD
Methyl aminolevulinate—Discomfort—Ezetimibe—atherosclerosis	0.00486	0.0083	CcSEcCtD
Methyl aminolevulinate—Pain—Rosuvastatin—atherosclerosis	0.00486	0.00828	CcSEcCtD
Methyl aminolevulinate—Infection—Lovastatin—atherosclerosis	0.00478	0.00816	CcSEcCtD
Methyl aminolevulinate—Infection—Ezetimibe—atherosclerosis	0.00469	0.008	CcSEcCtD
Methyl aminolevulinate—Discomfort—Simvastatin—atherosclerosis	0.00464	0.00791	CcSEcCtD
Methyl aminolevulinate—Urticaria—Rosuvastatin—atherosclerosis	0.00451	0.0077	CcSEcCtD
Methyl aminolevulinate—Oedema—Simvastatin—atherosclerosis	0.0045	0.00768	CcSEcCtD
Methyl aminolevulinate—Infection—Simvastatin—atherosclerosis	0.00447	0.00763	CcSEcCtD
Methyl aminolevulinate—Paraesthesia—Lovastatin—atherosclerosis	0.00432	0.00737	CcSEcCtD
Methyl aminolevulinate—Paraesthesia—Ezetimibe—atherosclerosis	0.00424	0.00723	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Class I MHC mediated antigen processing & presentation—SOCS3—atherosclerosis	0.00423	0.0102	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Innate Immune System—FCGR3A—atherosclerosis	0.0042	0.0102	CbGpPWpGaD
Methyl aminolevulinate—Discomfort—Pravastatin—atherosclerosis	0.00419	0.00715	CcSEcCtD
Methyl aminolevulinate—Hypersensitivity—Rosuvastatin—atherosclerosis	0.00418	0.00714	CcSEcCtD
Methyl aminolevulinate—Fatigue—Lovastatin—atherosclerosis	0.00415	0.00708	CcSEcCtD
Methyl aminolevulinate—Oedema—Niacin—atherosclerosis	0.00413	0.00705	CcSEcCtD
Methyl aminolevulinate—Pain—Lovastatin—atherosclerosis	0.00412	0.00702	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Interferon Signaling—ICAM1—atherosclerosis	0.00409	0.00987	CbGpPWpGaD
Methyl aminolevulinate—Asthenia—Rosuvastatin—atherosclerosis	0.00407	0.00695	CcSEcCtD
Methyl aminolevulinate—Oedema—Pravastatin—atherosclerosis	0.00407	0.00694	CcSEcCtD
Methyl aminolevulinate—Fatigue—Ezetimibe—atherosclerosis	0.00407	0.00694	CcSEcCtD
Methyl aminolevulinate—Infection—Pravastatin—atherosclerosis	0.00404	0.0069	CcSEcCtD
Methyl aminolevulinate—Paraesthesia—Simvastatin—atherosclerosis	0.00404	0.00689	CcSEcCtD
Methyl aminolevulinate—Pain—Ezetimibe—atherosclerosis	0.00404	0.00689	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Adaptive Immune System—FCGR3A—atherosclerosis	0.00403	0.00975	CbGpPWpGaD
Methyl aminolevulinate—Pruritus—Rosuvastatin—atherosclerosis	0.00402	0.00685	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Cytokine Signaling in Immune system—VCAM1—atherosclerosis	0.00401	0.00968	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Fcgamma receptor (FCGR) dependent phagocytosis—MAPK3—atherosclerosis	0.004	0.00967	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Cytokine Signaling in Immune system—SOCS3—atherosclerosis	0.00389	0.00939	CbGpPWpGaD
Methyl aminolevulinate—Fatigue—Simvastatin—atherosclerosis	0.00388	0.00662	CcSEcCtD
Methyl aminolevulinate—Pain—Simvastatin—atherosclerosis	0.00385	0.00657	CcSEcCtD
Methyl aminolevulinate—Urticaria—Lovastatin—atherosclerosis	0.00382	0.00652	CcSEcCtD
Methyl aminolevulinate—Dizziness—Rosuvastatin—atherosclerosis	0.00376	0.00641	CcSEcCtD
Methyl aminolevulinate—Urticaria—Ezetimibe—atherosclerosis	0.00375	0.0064	CcSEcCtD
Methyl aminolevulinate—Paraesthesia—Niacin—atherosclerosis	0.00371	0.00633	CcSEcCtD
Methyl aminolevulinate—Paraesthesia—Pravastatin—atherosclerosis	0.00365	0.00623	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Class I MHC mediated antigen processing & presentation—CD36—atherosclerosis	0.00358	0.00866	CbGpPWpGaD
Methyl aminolevulinate—Rash—Rosuvastatin—atherosclerosis	0.00358	0.00611	CcSEcCtD
Methyl aminolevulinate—Dermatitis—Rosuvastatin—atherosclerosis	0.00358	0.0061	CcSEcCtD
Methyl aminolevulinate—Urticaria—Simvastatin—atherosclerosis	0.00358	0.0061	CcSEcCtD
Methyl aminolevulinate—Headache—Rosuvastatin—atherosclerosis	0.00356	0.00607	CcSEcCtD
Methyl aminolevulinate—Hypersensitivity—Lovastatin—atherosclerosis	0.00355	0.00605	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Cytokine Signaling in Immune system—IL18—atherosclerosis	0.00354	0.00856	CbGpPWpGaD
Methyl aminolevulinate—Pain—Niacin—atherosclerosis	0.00353	0.00603	CcSEcCtD
Methyl aminolevulinate—Fatigue—Pravastatin—atherosclerosis	0.00351	0.00599	CcSEcCtD
Methyl aminolevulinate—Pain—Pravastatin—atherosclerosis	0.00348	0.00594	CcSEcCtD
Methyl aminolevulinate—Hypersensitivity—Ezetimibe—atherosclerosis	0.00348	0.00593	CcSEcCtD
Methyl aminolevulinate—Asthenia—Lovastatin—atherosclerosis	0.00345	0.00589	CcSEcCtD
Methyl aminolevulinate—Pruritus—Lovastatin—atherosclerosis	0.0034	0.00581	CcSEcCtD
Methyl aminolevulinate—Asthenia—Ezetimibe—atherosclerosis	0.00339	0.00578	CcSEcCtD
Methyl aminolevulinate—Nausea—Rosuvastatin—atherosclerosis	0.00337	0.00575	CcSEcCtD
Methyl aminolevulinate—Pruritus—Ezetimibe—atherosclerosis	0.00334	0.0057	CcSEcCtD
Methyl aminolevulinate—Hypersensitivity—Simvastatin—atherosclerosis	0.00332	0.00566	CcSEcCtD
Methyl aminolevulinate—Urticaria—Niacin—atherosclerosis	0.00328	0.0056	CcSEcCtD
Methyl aminolevulinate—Urticaria—Pravastatin—atherosclerosis	0.00323	0.00551	CcSEcCtD
Methyl aminolevulinate—Asthenia—Simvastatin—atherosclerosis	0.00323	0.00551	CcSEcCtD
Methyl aminolevulinate—Pruritus—Simvastatin—atherosclerosis	0.00318	0.00543	CcSEcCtD
Methyl aminolevulinate—Dizziness—Lovastatin—atherosclerosis	0.00318	0.00543	CcSEcCtD
Methyl aminolevulinate—Dizziness—Ezetimibe—atherosclerosis	0.00312	0.00532	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Interferon Signaling—IFNG—atherosclerosis	0.00311	0.00751	CbGpPWpGaD
Methyl aminolevulinate—Hypersensitivity—Niacin—atherosclerosis	0.00305	0.00519	CcSEcCtD
Methyl aminolevulinate—Rash—Lovastatin—atherosclerosis	0.00303	0.00518	CcSEcCtD
Methyl aminolevulinate—Dermatitis—Lovastatin—atherosclerosis	0.00303	0.00517	CcSEcCtD
Methyl aminolevulinate—Headache—Lovastatin—atherosclerosis	0.00301	0.00514	CcSEcCtD
Methyl aminolevulinate—Hypersensitivity—Pravastatin—atherosclerosis	0.003	0.00511	CcSEcCtD
Methyl aminolevulinate—Dizziness—Simvastatin—atherosclerosis	0.00298	0.00508	CcSEcCtD
Methyl aminolevulinate—Rash—Ezetimibe—atherosclerosis	0.00298	0.00508	CcSEcCtD
Methyl aminolevulinate—Dermatitis—Ezetimibe—atherosclerosis	0.00297	0.00507	CcSEcCtD
Methyl aminolevulinate—Asthenia—Niacin—atherosclerosis	0.00297	0.00506	CcSEcCtD
Methyl aminolevulinate—Headache—Ezetimibe—atherosclerosis	0.00296	0.00504	CcSEcCtD
Methyl aminolevulinate—Pruritus—Niacin—atherosclerosis	0.00292	0.00499	CcSEcCtD
Methyl aminolevulinate—Asthenia—Pravastatin—atherosclerosis	0.00292	0.00498	CcSEcCtD
Methyl aminolevulinate—Pruritus—Pravastatin—atherosclerosis	0.00288	0.00491	CcSEcCtD
Methyl aminolevulinate—Nausea—Lovastatin—atherosclerosis	0.00286	0.00488	CcSEcCtD
Methyl aminolevulinate—Rash—Simvastatin—atherosclerosis	0.00284	0.00484	CcSEcCtD
Methyl aminolevulinate—Dermatitis—Simvastatin—atherosclerosis	0.00284	0.00484	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Adaptive Immune System—NCF1—atherosclerosis	0.00282	0.00683	CbGpPWpGaD
Methyl aminolevulinate—Headache—Simvastatin—atherosclerosis	0.00282	0.00481	CcSEcCtD
Methyl aminolevulinate—Nausea—Ezetimibe—atherosclerosis	0.0028	0.00478	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Innate Immune System—CCR2—atherosclerosis	0.00278	0.00671	CbGpPWpGaD
Methyl aminolevulinate—Dizziness—Niacin—atherosclerosis	0.00273	0.00466	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Cytokine Signaling in Immune system—ICAM1—atherosclerosis	0.00273	0.00659	CbGpPWpGaD
Methyl aminolevulinate—Dizziness—Pravastatin—atherosclerosis	0.00269	0.00459	CcSEcCtD
Methyl aminolevulinate—Nausea—Simvastatin—atherosclerosis	0.00267	0.00456	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Adaptive Immune System—CYBA—atherosclerosis	0.00266	0.00642	CbGpPWpGaD
Methyl aminolevulinate—Rash—Niacin—atherosclerosis	0.00261	0.00445	CcSEcCtD
Methyl aminolevulinate—Dermatitis—Niacin—atherosclerosis	0.0026	0.00444	CcSEcCtD
Methyl aminolevulinate—Headache—Niacin—atherosclerosis	0.00259	0.00442	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Innate Immune System—TLR2—atherosclerosis	0.00258	0.00624	CbGpPWpGaD
Methyl aminolevulinate—Rash—Pravastatin—atherosclerosis	0.00257	0.00438	CcSEcCtD
Methyl aminolevulinate—Dermatitis—Pravastatin—atherosclerosis	0.00256	0.00437	CcSEcCtD
Methyl aminolevulinate—Headache—Pravastatin—atherosclerosis	0.00255	0.00435	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Adaptive Immune System—CD40—atherosclerosis	0.00248	0.00599	CbGpPWpGaD
Methyl aminolevulinate—Nausea—Niacin—atherosclerosis	0.00246	0.00419	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Immune System—FCGR3A—atherosclerosis	0.00245	0.00591	CbGpPWpGaD
Methyl aminolevulinate—Nausea—Pravastatin—atherosclerosis	0.00242	0.00412	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Innate Immune System—CD14—atherosclerosis	0.00233	0.00563	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Interferon Signaling—MAPK3—atherosclerosis	0.00222	0.00537	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Adaptive Immune System—VCAM1—atherosclerosis	0.00216	0.00521	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Adaptive Immune System—SOCS3—atherosclerosis	0.00209	0.00506	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Cytokine Signaling in Immune system—IFNG—atherosclerosis	0.00208	0.00502	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Innate Immune System—AGER—atherosclerosis	0.00191	0.00461	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Adaptive Immune System—CD40LG—atherosclerosis	0.0019	0.00459	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Innate Immune System—PRKCG—atherosclerosis	0.00189	0.00457	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Cytokine Signaling in Immune system—IL1B—atherosclerosis	0.00185	0.00447	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Innate Immune System—CD36—atherosclerosis	0.00185	0.00446	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Adaptive Immune System—CD36—atherosclerosis	0.00177	0.00428	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Cytokine Signaling in Immune system—NFKB1—atherosclerosis	0.00173	0.00417	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—NCF1—atherosclerosis	0.00171	0.00414	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Innate Immune System—PDGFB—atherosclerosis	0.0017	0.00412	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Innate Immune System—CRP—atherosclerosis	0.00166	0.00402	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Adaptive Immune System—PDGFB—atherosclerosis	0.00164	0.00395	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—CCR2—atherosclerosis	0.00162	0.00391	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—CYBA—atherosclerosis	0.00161	0.00389	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Innate Immune System—TLR4—atherosclerosis	0.0016	0.00386	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Cytokine Signaling in Immune system—STAT3—atherosclerosis	0.00155	0.00375	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—CD40—atherosclerosis	0.0015	0.00364	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—TLR2—atherosclerosis	0.0015	0.00364	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Cytokine Signaling in Immune system—MAPK3—atherosclerosis	0.00148	0.00358	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Adaptive Immune System—ICAM1—atherosclerosis	0.00147	0.00355	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—CD14—atherosclerosis	0.00136	0.00328	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—VCAM1—atherosclerosis	0.00131	0.00316	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—SOCS3—atherosclerosis	0.00127	0.00307	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—IL18—atherosclerosis	0.00116	0.0028	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—CD40LG—atherosclerosis	0.00115	0.00279	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—AGER—atherosclerosis	0.00111	0.00269	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—PRKCG—atherosclerosis	0.0011	0.00266	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Cytokine Signaling in Immune system—IL6—atherosclerosis	0.00108	0.00262	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—CD36—atherosclerosis	0.00108	0.0026	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—PDGFB—atherosclerosis	0.000992	0.0024	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—CRP—atherosclerosis	0.000969	0.00234	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Innate Immune System—NFKB1—atherosclerosis	0.000969	0.00234	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Innate Immune System—MAPK8—atherosclerosis	0.000952	0.0023	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Adaptive Immune System—NFKB1—atherosclerosis	0.00093	0.00225	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—TLR4—atherosclerosis	0.000929	0.00225	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—ICAM1—atherosclerosis	0.000891	0.00215	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Innate Immune System—MAPK3—atherosclerosis	0.000832	0.00201	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—IFNG—atherosclerosis	0.000678	0.00164	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Innate Immune System—IL6—atherosclerosis	0.000608	0.00147	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—IL1B—atherosclerosis	0.000605	0.00146	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—NFKB1—atherosclerosis	0.000564	0.00136	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Innate Immune System—AKT1—atherosclerosis	0.000561	0.00136	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—MAPK8—atherosclerosis	0.000554	0.00134	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Adaptive Immune System—AKT1—atherosclerosis	0.000539	0.0013	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—STAT3—atherosclerosis	0.000507	0.00123	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—MAPK3—atherosclerosis	0.000484	0.00117	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—IL6—atherosclerosis	0.000354	0.000856	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—AKT1—atherosclerosis	0.000327	0.000789	CbGpPWpGaD
